Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles

• DOI: 10.3892/ijo.24.3.647
• Publication Date: 2014-03-10T03:29:30Z
• Authors: Kensuke Ochi; Yataro Daigo; Toyomasa Katagiri; Satoshi Nagayama; Tatsuhiko Tsunoda; Akira Myoui; Norifumi Naka; Nobuto Araki; Ikuo Kudawara; Makoto Ieguchi; Yoshiaki Toyama; Junya Toguchida; Hideki Yoshikawa; Yusuke Nakamura
• Keywords: Adult; Male; Antibiotics, Antineoplastic; DNA, Complementary; Adolescent; Down-Regulation; Antineoplastic Agents; Middle Aged; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; 0302 clinical medicine; Chemotherapy, Adjuvant; Doxorubicin; Cluster Analysis; Humans; Female; Ifosfamide; Cisplatin; Child; Antineoplastic Agents, Alkylating; Aged; Oligonucleotide Array Sequence Analysis

To establish a method for predicting the response to chemotherapy osteosarcoma (OS), we performed expression profile analysis using cDNA microarray consisting of 23,040 genes. Hierarchical clustering based on profiles 19 biopsy samples OS demonstrated two major clusters, one which consisted exclusively typical OS, i.e. conventional central in long bone patients second decade. A set genes was identified characterize this subgroup, some have previously indicated relation carcinogenesis. Thirteen were treated with an identical protocol containing doxorubicin, cis-platinum and ifosfamide, histological examination resected specimens after operation classified 6 cases as responder 7 non-responder. comparison these groups 60 whose levels likely be correlated (P<0.008). drug scoring (DRS) system developed genes, proved applicable predict irrespective subclassification OS. The reliability DRS further confirmed by testing additional 5 cases. These results that gene-expression might useful